Exhibit 99.1

Novartis AG ("Novartis"), Novartis Corporation ("Novartis Corp") and Zodnas
Acquisition Corp. ("Zodnas") each disclaim any beneficial ownership of the
Common Stock of the Issuer and pursuant to Exchange Act Rule 16a-1(a)(4), this
filing shall not be deemed an admission by either Novartis, Novartis Corp or
Zodnas of beneficial ownership of any Common Stock. Novartis, Novartis Corp and
Zodnas are filing this Form 3 because Novartis, Novartis Corp and Zodnas are
filing with the Securities and Exchange Commission a Schedule 13D with respect
to the Common Stock of the Issuer.

On February 20, 2005, Novartis Corp, Santo Holding (Deutschland) GmbH and
Novartis (as guarantor) entered into an Agreement for Purchase and Sale of Stock
(the "Santo Stock Purchase Agreement") relating to the purchase by Novartis Corp
(or its designee) of 60,000,000 shares of Common Stock of the Issuer
representing approximately 67.5% of the outstanding shares of Common Stock of
the Issuer. If Zodnas purchases any shares of Common Stock of the Issuer, Zodnas
will become the direct beneficial owner of the shares and Novartis Corp and
Novartis will become the indirect beneficial owners. If Novartis Corp purchases
any shares of Common Stock of the Issuer, Novartis Corp will become the direct
beneficial owner of the shares, and Novartis will become an indirect beneficial
owner.

On February 16 and 17, 2005, Novartis (Deutschland) GmbH ("Novartis
Deutschland") and Novartis (as guarantor) entered into the Hexal Purchase
Agreement (as defined in the Santo Stock Purchase Agreement) relating to the
acquisition of shares in A+T Vermogensverwaltung GmbH as well as partnership
interests in A+T Holding GmbH & Co. KG (the "Hexal Business"). In connection
with the purchase of the Hexal Business, Novartis Deutschland will acquire
132,122 shares of Common Stock of the Issuer currently held by the companies
comprising the Hexal Business, which represents approximately .1% of the
outstanding shares of Common Stock. Novartis will become the indirect beneficial
owner of any shares of Common Stock of the Issuer owned by Novartis Deutschland.

For further information, refer to our Schedule 13D filed with the Securities and
Exchange Commission.